In pharmaceutical R&D, most leaders believe the constraints are scientific: new biology, rare targets, combinatorial complexity. But across the industry, promising drug discovery pipelines are being delayed – not by a lack of scientific progress, but by infrastructure that can’t keep pace. The next transformative molecule won’t be held back by biology – it will…